Literature DB >> 23616960

Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre.

Adam Isaiah Newman1, Shelley Beckstead, David Beking, Susan Finch, Tina Knorr, Carol Lynch, Meredith MacKenzie, Daphne Mayer, Brenda Melles, Ron Shore.   

Abstract

The aim of the present prospective observational study was to assess uptake and success of hepatitis C virus (HCV) treatment among a group of former and current injection drug users with chronic HCV infection at the Street Health Centre in Kingston, Ontario. The Street Health Centre offers hepatitis C education, assessment and treatment within a multidisciplinary, integrated and collaborative treatment model of care delivered by primary care professionals. The study enrolled a convenience sample of 34 patients. Seventy per cent of study patients had no postsecondary education, 85% were unemployed and one-third were unstably housed. A majority of study patients self-reported mental health problems. Of the 14 patients who initiated antiviral treatment in the study period, eight (57%) achieved sustained virological response. Regardless of virological outcome, patients who initiated treatment showed positive trends toward increased social and psychiatric stability, and decreases in high-risk behaviours. These results suggest that not only is successful treatment of chronic HCV infection in current and former injection drug users with concurrent psychiatric disorders possible, but the benefits of such treatment delivered in a community-based, multidisciplinary, primary care model may extend beyond narrowly defined virological outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23616960      PMCID: PMC3742479          DOI: 10.1155/2013/515636

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  38 in total

Review 1.  Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review.

Authors:  E Dieperink; M Willenbring; S B Ho
Journal:  Am J Psychiatry       Date:  2000-06       Impact factor: 18.112

2.  Hepatitis C, illicit drug use and public health: does Canada really have a viable plan?

Authors:  Benedikt Fischer; Kate Kalousek; Jürgen Rehm; Jeff Powis; Mel Krajden; Jens Reimer
Journal:  Can J Public Health       Date:  2006 Nov-Dec

3.  Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities.

Authors:  Holly Hagan; Mary H Latka; Jennifer V Campbell; Elizabeth T Golub; Richard S Garfein; David A Thomas; Farzana Kapadia; Steffanie A Strathdee
Journal:  Clin Infect Dis       Date:  2006-01-20       Impact factor: 9.079

4.  Psychiatric morbidity and its effect on the quality of life of patients with chronic hepatitis B and hepatitis C.

Authors:  Mine Ozkan; Aytül Corapçioglu; Ibrahim Balcioglu; Erhan Ertekin; Sila Khan; Samuray Ozdemir; Deniz Karayün; Bariş Onen Unsalver; Nazmiye Kocaman; Sabahattin Kaymakglu; Gültürk Köroglu
Journal:  Int J Psychiatry Med       Date:  2006       Impact factor: 1.210

5.  Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients.

Authors:  Nina Ebner; Christian Wanner; Bernadette Winklbaur; Christian Matzenauer; Crispa Aeschbach Jachmann; Kenneth Thau; Gabriele Fischer
Journal:  Addict Biol       Date:  2009-04       Impact factor: 4.280

Review 6.  Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?

Authors:  Martin Schaefer; Andreas Heinz; Markus Backmund
Journal:  Addiction       Date:  2004-09       Impact factor: 6.526

Review 7.  Psychiatric side effects of interferon treatment.

Authors:  Scott B Patten
Journal:  Curr Drug Saf       Date:  2006-05

8.  Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.

Authors:  Jason Grebely; Krista Genoway; Milan Khara; Fiona Duncan; Mark Viljoen; Doug Elliott; Jesse D Raffa; Stanley DeVlaming; Brian Conway
Journal:  Int J Drug Policy       Date:  2007-04-27

9.  Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients.

Authors:  P Bruggmann; L Falcato; S Dober; B Helbling; O Keiser; F Negro; D Meili
Journal:  J Viral Hepat       Date:  2008-07-10       Impact factor: 3.728

10.  Therapeutic challenges in hepatitis C-infected injection drug using patients.

Authors:  Curtis L Cooper; Edward J Mills
Journal:  Harm Reduct J       Date:  2006-11-10
View more
  12 in total

Review 1.  Can antiviral treatment for hepatitis C be safely and effectively delivered in primary care?: a narrative systematic review of the evidence base.

Authors:  Iain F Brew; Christine Butt; Nat Wright
Journal:  Br J Gen Pract       Date:  2013-12       Impact factor: 5.386

Review 2.  Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.

Authors:  Jaimie P Meyer; Yavar Moghimi; Ruthanne Marcus; Joseph K Lim; Alain H Litwin; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2015-05-17

3.  Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.

Authors:  Maryam Alavi; Tim Spelman; Gail V Matthews; Paul S Haber; Carolyn Day; Ingrid van Beek; Nick Walsh; Barbara Yeung; Julie Bruneau; Kathy Petoumenos; Kate Dolan; John M Kaldor; Gregory J Dore; Margaret Hellard; Jason Grebely
Journal:  Int J Drug Policy       Date:  2015-05-21

4.  Impact of comprehensive care on health care use among a cohort of marginalized people living with hepatitis C in Toronto.

Authors:  Erin Mandel; Claire E Kendall; Kate Mason; Mary Guyton; Bernadette Lettner; Jennifer Broad; Jason Altenberg; Jessy Donelle; Jeff Powis
Journal:  Can Liver J       Date:  2020-06-04

5.  Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study.

Authors:  Alain H Litwin; John Jost; Katherine Wagner; Moonseong Heo; Alison Karasz; Judith Feinberg; Arthur Y Kim; Paula J Lum; Shruti H Mehta; Lynn E Taylor; Judith I Tsui; Irene Pericot-Valverde; Kimberly Page
Journal:  Contemp Clin Trials       Date:  2019-10-24       Impact factor: 2.226

6.  Clinical Characteristics and Treatment Efficasy of Chronic HCV Infection Among Intravenous Drug Users in Tuzla Canton.

Authors:  Jasminka Petrovic; Nermin Salkic; Dilista Piljic; Sead Ahmetagic; Rahima Jahic; Humera Porobic; Arnela Smriko-Nuhanovic; Mevludin Hasanovic
Journal:  Mater Sociomed       Date:  2018-12

7.  A systematic review of community based hepatitis C treatment.

Authors:  Amanda J Wade; Vanessa Veronese; Margaret E Hellard; Joseph S Doyle
Journal:  BMC Infect Dis       Date:  2016-05-16       Impact factor: 3.090

8.  Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial.

Authors:  A J Wade; J S Doyle; E Gane; C Stedman; B Draper; D Iser; S K Roberts; W Kemp; D Petrie; N Scott; P Higgs; P A Agius; J Roney; L Stothers; A J Thompson; M E Hellard
Journal:  Trials       Date:  2018-07-16       Impact factor: 2.279

9.  From client to co-worker: a case study of the transition to peer work within a multi-disciplinary hepatitis c treatment team in Toronto, Canada.

Authors:  Paula Tookey; Kate Mason; Jennifer Broad; Marty Behm; Lise Bondy; Jeff Powis
Journal:  Harm Reduct J       Date:  2018-08-14

Review 10.  Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment.

Authors:  Caroline O'Keefe-Markman; Kristina Dawn Lea; Christopher McCabe; Elaine Hyshka; Tania Bubela
Journal:  BMC Public Health       Date:  2020-01-20       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.